System would use microbes for manufacturing small amounts of vaccines and other therapies.
For medics on the battlefield and doctors in remote or developing parts of the world, getting rapid access to the drugs needed to treat patients can be challenging.
Biopharmaceutical drugs, which are used in a wide range of therapies including vaccines and treatments for diabetes and cancer, are typically produced in large, centralized fermentation plants. This means they must be transported to the treatment site, which can be expensive, time-consuming, and challenging to execute in areas with poor supply chains.
Now a portable production system, designed to manufacture a range of biopharmaceuticals on demand, has been developed by researchers at MIT, with funding from the Defense Advanced Research Projects Agency (DARPA).
In a paper published today in the journal Nature Communications, the researchers demonstrate that the system can be used to produce a single dose of treatment from a compact device containing a small droplet of cells in a liquid.
In this way, the system could ultimately be carried onto the battlefield and used to produce treatments at the point of care. It could also be used to manufacture a vaccine to prevent a disease outbreak in a remote village, according to senior author Tim Lu, an associate professor of biological engineering and electrical engineering and computer science, and head of the Synthetic Biology Group at MIT’s Research Laboratory of Electronics.
“Imagine you were on Mars or in a remote desert, without access to a full formulary, you could program the yeast to produce drugs on demand locally,” Lu says.
The system is based on a programmable strain of yeast, Pichia pastoris, which can be induced to express one of two therapeutic proteins when exposed to a particular chemical trigger. The researchers chose P. pastoris because it can grow to very high densities on simple and inexpensive carbon sources, and is able to express large amounts of protein.
“We altered the yeast so it could be more easily genetically modified, and could include more than one therapeutic in its repertoire,” Lu says.
When the researchers exposed the modified yeast to estrogen ?-estradiol, the cells expressed recombinant human growth hormone (rHGH). In contrast, when they exposed the cells to methanol, the yeast expressed the protein interferon.
The cells are held within a millimeter-scale table-top microbioreactor, containing a microfluidic chip, which was originally developed by Rajeev Ram, a professor of electrical engineering at MIT, and his team, and then commercialized by Kevin Lee — an MIT graduate and co-author — through a spin-off company.
A liquid containing the desired chemical trigger is first fed into the reactor, to mix with the cells.
Inside the reactor, the cell-and-chemical mixture is surrounded on three sides by polycarbonate; on the fourth side is a flexible and gas-permeable silicone rubber membrane.
By pressurizing the gas above this membrane, the researchers are able to gently massage the liquid droplet to ensure its contents are fully mixed together.
“This makes sure that the one milliliter (of liquid) is homogenous, and that is important because diffusion at these small scales, where there is no turbulence, takes a surprisingly long time,” says Ram, who was also a senior author of the paper.
Because the membrane is gas permeable, it allows oxygen to flow through to the cells, while any carbon dioxide they produce can be easily extracted.
The device continuously monitors conditions within the microfluidic chip, including oxygen levels, temperature, and pH, to ensure the optimum environment for cell growth. It also monitors cell density.
If the yeast is required to produce a different protein, the liquid is simply flushed through a filter, leaving the cells behind. Fresh liquid containing a new chemical trigger can then be added, to stimulate production of the next protein.
Although other research teams have previously attempted to build microbioreactors, these have not have not had the ability to retain the protein-producing cells while flushing out the liquid they are mixed with, Ram says. “You want to keep the cells because they are your factory,” he says. “But you also want to rapidly change their chemical environment, in order to change the trigger for protein production.”
The researchers have demonstrated a very logical and practical way to produce biologic drugs, according to Luke P. Lee, a professor of bioengineering at the University of California at Berkeley, who was not involved in the research. Their smart biologics production technique uses one of the best integrated microfluidics systems, Lee says.
“It is a pragmatic solution for biomanufacturing, and the team’s flexible and portable platform shows an authentic way of producing personalized therapeutics,” he says.
The researchers are now investigating the use of the system in combinatorial treatments, in which multiple therapeutics, such as antibodies, are used together.
Combining multiple therapeutics in this way can be expensive if each requires its own production line, Lu says.
“But if you could engineer a single strain, or maybe even a consortia of strains that grow together, to manufacture combinations of biologics or antibodies, that could be a very powerful way of producing these drugs at a reasonable cost,” he says.
The Latest on: Biopharmaceuticals
via Google News
The Latest on: Biopharmaceuticals
- Thawing System Market 2019 Emerging Growth with Size, Share, Trend, Analysis Growing Opportunity, key players by 2023on November 15, 2019 at 5:55 pm
Thawing system is mainly used for safe storage and transport of various biopharmaceuticals products which are used for various research purposes. Due to increasing focus on research and development of ...
- NGM Biopharmaceuticals, Inc. Third-Quarter Results: Here's What Analysts Are Forecasting For Next Yearon November 15, 2019 at 7:59 am
It's been a pretty great week for NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) shareholders, with its shares surging 12% to US$14.15 in the week since its latest third-quarter results. Revenues came in ...
- Eiger to Present at Jefferies 2019 London Healthcare Conferenceon November 15, 2019 at 7:52 am
PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...
- BRIEF-Sienna Biopharmaceuticals Announces Court Approval Of Chapter 11 Bidding Procedureson November 14, 2019 at 1:56 pm
Nov 14 (Reuters) - Sienna Biopharmaceuticals Inc: * SIENNA BIOPHARMACEUTICALS ANNOUNCES COURT APPROVAL OF CHAPTER 11 BIDDING PROCEDURES * SIENNA - ON NOV 13 U.S. BANKRUPTCY COURT FOR DISTRICT OF ...
- NGM Biopharmaceuticals EPS beats by $0.17, beats on revenueon November 12, 2019 at 6:32 pm
NGM Biopharmaceuticals (NASDAQ:NGM): Q3 GAAP EPS of -$0.17 beats by $0.17. Revenue of $21.57M (+3.6% Y/Y) beats by $3.7M.
- NGM Biopharmaceuticals: 3Q Earnings Snapshoton November 12, 2019 at 4:02 pm
SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Tuesday reported a loss of $10.9 million in its third quarter. On a per-share basis, the South San Francisco, California-based ...
- Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?on November 11, 2019 at 2:13 pm
One of these stocks was Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR). Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has seen a decrease in support from the world's most elite money managers recently.
- NGM Biopharmaceuticals, Inc. Common Stock (NGM) Earnings Report Dateon November 10, 2019 at 8:59 pm
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago ...
- Single Use Technologies for Biopharmaceuticals Market 2019-2026: Focusing Top Key Players like EMD Millipore, GE Healthcare, Pall Corpon November 10, 2019 at 8:25 pm
Nov 11, 2019 (Market Prediction via COMTEX) -- Global Single Use Technologies for Biopharmaceuticals Market 2019 Size, forecast and overview on current market trends. The latest trending report Global ...
- The Paradigm Biopharmaceuticals share price is up 196% in 2019on November 8, 2019 at 10:51 am
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was on form again on Thursday. The biopharmaceutical company’s shares pushed 4% higher to $2.93 on the day of its annual general meeting.
via Bing News